Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in AF Rhythm Control
NCT06759909Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Freedom from any atrial arrhythmia at 9 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06759909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759909.